Ellen Holm Nielsen

Corporate Officer/Principal bei University of Southern Denmark

Consumer Services

Health Technology

Profil

Ellen Holm Nielsen is currently a Principal at the University of California, Berkeley, the University of Copenhagen, the University of Southern Denmark, and Albert Einstein College of Medicine, Inc. She previously worked as a Director at Profylakse ApS.

Aktive Positionen von Ellen Holm Nielsen

Unternehmen	Position	Beginn
University of Southern Denmark	Corporate Officer/Principal	-
University of California, Berkeley	Corporate Officer/Principal	-
Albert Einstein College of Medicine, Inc.	Corporate Officer/Principal	14.08.2009
University of Copenhagen	Corporate Officer/Principal	-

Alle aktiven Positionen von Ellen Holm Nielsen

Ehemalige bekannte Positionen von Ellen Holm Nielsen

Unternehmen	Position	Ende
Profylakse ApS Profylakse ApS Pharmaceuticals: MajorHealth Technology Profylakse is a Danish biotech company, founded in 1999 by scientists from University of Southern Denmark. Profylakse has an experienced development team, working within microbiology, immunology and protein chemistry for 3 decades. Its focus is on the development of antiviral, not vaccines, especially against influenza and parainfluenza viruses. This has resulted in its antiviral recombinant SAP. Profylakse´s investor base is the Danish Technological Institute and the South Danish Innovations.	Direktor/Vorstandsmitglied	22.11.2013

Sehen Sie sich die Erfahrung von Ellen Holm Nielsen im Detail an

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Ellen Holm Nielsen im Detail an

Beziehungen

100 +

Beziehungen ersten Grades

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Private Unternehmen	1
Profylakse ApS Profylakse ApS Pharmaceuticals: MajorHealth Technology Profylakse is a Danish biotech company, founded in 1999 by scientists from University of Southern Denmark. Profylakse has an experienced development team, working within microbiology, immunology and protein chemistry for 3 decades. Its focus is on the development of antiviral, not vaccines, especially against influenza and parainfluenza viruses. This has resulted in its antiviral recombinant SAP. Profylakse´s investor base is the Danish Technological Institute and the South Danish Innovations.	Health Technology